Skip to main content

Table 6 Effect of EMZSB on blood glucose level in alloxan-induced diabetic rats

From: Screening of Manilkara zapota (L) P. Royen stem bark ethanolic extract for in vitro α-glucosidase inhibition, preliminary antidiabetic effects, and improvement of diabetes and its complications in alloxan-induced diabetes in Wistar rats

Groups Blood glucose level (mg dl−1) at
1st day 7th day 14th day 21st day
Normal control 70.36 ± 3.46 72.57 ± 4.55 74.81 ± 3.58 72.67 ± 4.29
Diabetic control 245.58 ± 9.58$ 258.85 ± 10.59$ 265.98 ± 12.58$ 270.29 ± 10.67$
Diabetic + Glimepiride 265.85 ± 10.98 234.28 ± 8.75 205.58 ± 11.65** 186.68 ± 12.34***
Diabetic + EMZSB 150 259.58 ± 7.64 249.74 ± 12.58 243.98 ± 7.38 233.87 ± 8.74
Diabetic + EMZSB 200 258.64 ± 11.47 245.75 ± 10.48 239.67 ± 10.53 214.52 ± 8.75*
Diabetic + EMZSB 250 255.52 ± 12.53 242.68 ± 10.31 219.42 ± 8.78 198.68 ± 9.52**
  1. Values were presented as mean ± SEM (n = 6); statistics employed was two-way ANOVA followed by Tukey’s multiple comparison test. Diabetic animals when treated with EMZSB 250 showed a significant (p < 0.01) reduction in the blood glucose levels on 21st day. $p < 0.001
  2. When compared with diabetic control; *p < 0.05, **p < 0.01, and ***p < 0.001